TY  - INPR
JF  - JAMA Oncology
A1  - Leone, Gianmarco
A1  - Orlando, Francesco
A1  - Dutey-Magni, Peter
A1  - Vainauskas, Osvaldas
A1  - Grist, Emily
A1  - Ciani, Yari
A1  - Lall, Sharanpreet
A1  - Thakali, Suparna
A1  - Wingate, Anna
A1  - Wetterskog, Daniel
A1  - Sachdeva, Ashwin
A1  - Sydes, Matthew R
A1  - McPhail, Neil
A1  - Sreenivasan, Thiagarajan
A1  - O'Sullivan, Joe M
A1  - Clarke, Noel W
A1  - Parmar, Mahesh KB
A1  - Brown, Louise C
A1  - James, Nicholas D
A1  - Demichelis, Francesca
A1  - Attard, Gerhardt
A1  - the STAMPEDE collaborators
N2  - We previously reported that abiraterone acetate and prednisolone (hereafter abiraterone) added at initiation of androgen deprivation therapy (ADT) improved survival of metastatic and very high-risk locally advanced prostate cancer and that combining with enzalutamide did not change efficacy.1 Using next-generation sequencing on plasma DNA, we previously showed that genomic alterations of the androgen receptor (AR) gene contribute to resistance to abiraterone or enzalutamide when initiated for metastatic castration-resistant prostate cancer after progression with ADT alone.2 It is unknown whether hormone intensification at start of ADT alters selection of AR alterations within the gene body and/or enhancer region.3
ID  - discovery10205615
PB  - American Medical Association
UR  - https://doi.org/10.1001/jamaoncol.2024.7051
SN  - 2374-2437
N1  - This version is the author accepted manuscript. For information on re-use, please refer to the publisher?s terms and conditions.
TI  - Plasma AR Alterations and Timing of Intensified Hormone Treatment for Prostate Cancer:
the STAMPEDE Phase 3 Randomized Clinical Trial
AV  - public
Y1  - 2025/02/27/
ER  -